|
|
|
篇目详细内容 |
|
【篇名】 |
Prospective research on the efficacy and safety of oxcarbazepine as monotherapy and add-on therapy for partial epilepsy |
|
【刊名】 |
Frontiers of Medicine in China |
|
【刊名缩写】 |
Front. Med. China |
|
【ISSN】 |
1673-7342 |
|
【EISSN】 |
1673-7458 |
|
【DOI】 |
10.1007/s11684-009-0025-6 |
|
【出版社】 |
Higher Education Press and Springer-Verlag |
|
【出版年】 |
2009 |
|
【卷期】 |
3
卷2期 |
|
【页码】 |
181-186
页,共
6
页 |
|
【作者】 |
Huicong KANG MD;
Xiaoyan LIU MM;
Hu QI MM;
Feng XU MM;
Xiang LI BM;
Yuan WANG BM;
Zhiguang LIU BM;
Suiqiang ZHU MD;
|
|
【关键词】 |
oxcarbazepine; partial epilepsy |
【摘要】 |
|
The purpose of our research was to evaluate the efficacy, tolerance, and safety of oxcarbazepine (OXC) as monotherapy and add-on therapy for partial epilepsy. We carried out a prospective clinical follow-up trial at the Epilepsy Center of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Sixty-seven patients with partial epilepsy received OXC therapy. The patients were randomly divided into a monotherapy group and an add-on therapy group. We observed the efficacy and safety in the first three months and the following three months respectively, and compared them with each other. There was a significant difference in the decrease of seizure frequency between the two groups (P = 0.002). There was a significant difference in the percentage of seizure-free between the monotherapy and the add-on therapy groups in the first three months (P = 0.02), and there were also statistical differences in the 50% response rate (P = 0.017) and the percentage of seizure-free in the following three months (P = 0.019). No difference was found in the 50% response rate, the 75% response rate, and the percentage of seizure-free between the first three months and the following three months in the whole group and the two subgroups (P > 0.05). The incidence rate of side effects due to the therapy was 19.40% (13 of 67). The side effects were mainly found in the first three months. It is concluded that OXC is the first-line anti-epileptic drug (AED) for partial seizures, and could be used as the monotherapy and add-on therapy for newly diagnosed patients and patients that failed to tolerate or benefit from other AEDs. |
|
